Second attempt to withdraw cabergoline in prolactinomas: a pilot study

被引：0
|
作者：
Ratchaneewan Kwancharoen
Renata Simona Auriemma
Gayane Yenokyan
Gary S. Wand
Annamaria Colao
Roberto Salvatori
机构：
[1] Johns Hopkins University School of Medicine,Division of Endocrinology and Metabolism, Department of Medicine, Pituitary Center
[2] Johns Hopkins University School of Public Health,Department of Biostatistics
[3] University “Federico II”,Sezione di Endocrinologia, Dipartimento di Medicina Clinica e Chirurgia
来源：
Pituitary | 2014年 / 17卷
关键词：
Cabergoline; Prolactinoma; Second withdrawal; Recurrence;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：451 / 456
页数：5
相关论文
共 50 条
  • [41] Treatment complexities in psychosis associated with cabergoline treatment in patients having pituitary prolactinomas
    Gupta, Prashant
    Tundup, Tashi
    Singh, Jawahar
    Deb, Koushik Sinha
    Verma, Rohit
    Kumar, Nand
    ASIAN JOURNAL OF PSYCHIATRY, 2018, 31 : 129 - 132
  • [42] Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas
    Sophie Vallette
    Karim Serri
    Juan Rivera
    Patricia Santagata
    Sophie Delorme
    Natasha Garfield
    Nora Kahtani
    Hugues Beauregard
    Nahla Aris-Jilwan
    Ghislaine Houde
    Omar Serri
    Pituitary, 2009, 12 : 153 - 157
  • [43] Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas
    Vallette, Sophie
    Serri, Karim
    Rivera, Juan
    Santagata, Patricia
    Delorme, Sophie
    Garfield, Natasha
    Kahtani, Nora
    Beauregard, Hugues
    Aris-Jilwan, Nahla
    Houde, Ghislaine
    Serri, Omar
    PITUITARY, 2009, 12 (03) : 153 - 157
  • [44] Should colleges withdraw students who threaten or attempt suicide?
    Pavela, G
    JOURNAL OF AMERICAN COLLEGE HEALTH, 2006, 54 (06) : 367 - 371
  • [45] Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas
    Auriemma, Renata S.
    Pivonello, Rosario
    Perone, Ylenia
    Grasso, Ludovica F. S.
    Ferreri, Lucia
    Simeoli, Chiara
    Iacuaniello, Davide
    Gasperi, Maurizio
    Colao, Annamaria
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 169 (03) : 359 - 366
  • [46] Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment
    Bueno, C. B. F.
    Trarbach, E. B.
    Bronstein, M. D.
    Glezer, A.
    PITUITARY, 2017, 20 (03) : 295 - 300
  • [47] Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment
    CBF Bueno
    EB Trarbach
    MD Bronstein
    A Glezer
    Pituitary, 2017, 20 : 295 - 300
  • [48] High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?
    Espinosa-Cardenas, Etual
    Sanchez-Garcia, Miriam
    Ramirez-Renteria, Claudia
    Mendoza-Zubieta, Victoria
    Sosa-Eroza, Ernesto
    Mercado, Moises
    ENDOCRINE, 2020, 70 (01) : 143 - 149
  • [49] High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?
    Etual Espinosa-Cárdenas
    Miriam Sánchez-García
    Claudia Ramírez-Rentería
    Victoria Mendoza-Zubieta
    Ernesto Sosa-Eroza
    Moises Mercado
    Endocrine, 2020, 70 : 143 - 149
  • [50] Letter to “High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?”
    Burcu Candemir
    Şafak Akın
    Endocrine, 2021, 71 : 262 - 262
12345